Breckenridge Pharmaceutical, Inc. v. Hetero USA Inc.
1:24-cv-00571
Overview
Parties
Defendant
Camber Pharmaceuticals, Inc. Operating Company
Represented By
7 Attorneys ListedMorris James LLP
3205 Avenue North Boulevard, Suite 100
Morris James LLP
3205 Avenue North Boulevard, Suite 100
Hetero Labs Limited. NPE (University / Research)
Represented By
7 Attorneys ListedMorris James LLP
3205 Avenue North Boulevard, Suite 100
Morris James LLP
3205 Avenue North Boulevard, Suite 100
Hetero Labs Limited Unit - III NPE (University / Research)
Represented By
7 Attorneys ListedMorris James LLP
3205 Avenue North Boulevard, Suite 100
Morris James LLP
3205 Avenue North Boulevard, Suite 100
Hetero USA Inc. Operating Company
Represented By
7 Attorneys ListedMorris James LLP
3205 Avenue North Boulevard, Suite 100
Morris James LLP
3205 Avenue North Boulevard, Suite 100
Plaintiff
Breckenridge Pharmaceutical, Inc. Operating Company
Represented By
6 Attorneys ListedRichards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & FInger
Richards, Layton & FInger, General Litigation
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Special Master
Chad S.C. Stover NPE (Individual / Inventor)
Represented By
0 Attorneys ListedCourt & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 3 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | Asserted Patent | View Official Patent → |
| 🌐 PCT International (WIPO) | PCT World Application | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → |
MSN Pharmaceuticals, Inc. et al. v. Breckenridge Pharmaceutical, Inc.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US11013729
Oral pharmaceutical compositions of dabigatran etexilate
|
Filed: 2013-02-21
Issued: 2021-05-25
|
Active (7.1 yrs remaining)
+321d PTA
Expires: 2034-01-08
|
|
|
US11752142
Oral pharmaceutical compositions of dabigatran etexilate
|
Filed: 2021-04-27
Issued: 2023-09-12
|
Active (14.4 yrs remaining)
Expires: 2041-04-27
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term; injunctive relief viable.
High PTA (+321 days) / In re Cellect scrutiny applies.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th Year Maintenance Fee Paid (8th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
89
Dispositive
33
Granted
0
Denied
0
Pending / Review
74
Motions by Category
Key Dispositive Motions & Rulings